Price (delayed)
$18.94
Market cap
$370.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.7
Enterprise value
$164.2M
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and
There are no recent dividends present for ALBO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.